Search Results

Resources & Infrastructure

The Abigail Wexner Research Institute at Nationwide Children's Hospital has a wealth of resources available to our researchers to ensure they have the tools they need to continue our mission of enhancing the health of children by engaging in high quality, cutting-edge research according to the

Article

CRISPR / Gene Editing Core

The team of experts available through the CRISPR/Gene Editing Core at Nationwide Children’s, in collaboration with The Ohio State University, provides investigators at both institutions with CRISPR/Gene Editing services with reasonable turnaround times and at affordable prices.

Article

Timothy Cripe Lab

Under the direction of Timothy Cripe, MD, PhD, the Cripe Lab focuses on developing and testing new, targeted therapies for pediatric solid tumors and translating those findings into clinical studies.

Article

Timothy Cripe Lab Staff

Timothy P. Cripe, MD, PhD Principal Investigator Timothy Cripe, MD, PhD, is the chief of the Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant and the Gordon Teter endowed chair in pediatric cancer at Nationwide Children’s Hospital.

Article

Besner Lab

The Besner Lab at Nationwide Children’s aims to eliminate necrotizing enterocolitis (NEC) and its downstream consequences.

Article

Besner Lab Staff

Learn more about principal investigator Gail Besner, MD, and her dynamic team in the Besner Lab.

News

FDA Approves First Gene Therapy Treatment for SMA Developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital

Today, the Abigail Wexner Research Institute at Nationwide Children’s Hospital praised the Food and Drug Administration (FDA) for its approval of Zolgensma^® for spinal muscular atrophy (SMA) following decades of research in its Center for Gene Therapy to help patients with neuromuscular diseases.

News

FDA Approves First Gene Therapy Treatment for Duchenne Muscular Dystrophy Developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital

Today, the Abigail Wexner Research Institute at Nationwide Children’s Hospital praised the Food and Drug Administration (FDA) for its accelerated approval of SRP-9001/ELEVIDYS for Duchenne muscular dystrophy (DMD) following decades of research in its Center for Gene Therapy to help patients with neuromuscular diseases.

Provider

Kevin M Flanigan

Kevin M. Flanigan, MD, is an attending neurologist at Nationwide Children's and director of the Jerry R. Mendell Center for Gene Therapy in the Abigail Wexner Research Institute at Nationwide Children's Hospital.